Results 321 to 330 of about 1,213,487 (359)
Some of the next articles are maybe not open access.
Alternatives to the Kaplan–Meier estimator of progression-free survival
The International Journal of Biostatistics, 2020Abstract Progression-free survival (PFS), defined as the time from randomization to progression of disease or death, has been indicated as an endpoint to support accelerated approval of certain cancer drugs by the U.S. FDA. The standard Kaplan–Meier (KM) estimator of PFS, however, can result in significantly biased estimates.
Molin Wang +5 more
openaire +3 more sources
Progression-free survival as a surrogate for overall survival in advanced cancer.
Journal of Clinical Oncology, 2015e17765 Background: Progression-free survival (PFS) is sometimes being used instead of overall survival (OS) as a primary end-point in clinical trials of advanced cancer patients (ACP).
Eric Gillies +2 more
openaire +2 more sources
Mitotic Index and Progression-Free Survival in Atypical Meningiomas
World Neurosurgery, 2020Extent of resection and tumor grade are considered the most important predictors of progression-free survival (PFS) in meningiomas. However, adjuvant therapy for atypical meningiomas remains controversial, with variable PFS rates of up to 40%. The current mitotic index (MI) range for atypical meningiomas is broad, comprising all tumors with >4 and
Ricardo A. Domingo +5 more
openaire +3 more sources
Population kinetics of progression free survival (PFS).
Journal of Clinical Oncology, 2019e18251 Background: We assessed drug type impact on whether PFS curves could be fit by 2 phase decay models on nonlinear regression analysis (NLRA). Methods: We digitized 894 published PFS curves for incurable cancers. We used GraphPad Prism 7 for 1 phase and 2 phase decay NLRA, with constraints Y0 = 100 and plateau = 0. We defined curves as fitting 2
David J. Stewart +8 more
openaire +2 more sources
Sensitivity analysis of progression‐free survival with dependent withdrawal
Statistics in Medicine, 2008AbstractWe develop a sensitivity analysis method for comparing treatment‐specific distributions where the endpoint is progression‐free survival (PFS). The censoring process may be informative due to selective patient withdrawal, which occurs whenever disease evaluation has been discontinued without progression being documented. The sensitivity analysis
Robert Gray, Ping K. Ruan
openaire +3 more sources
A Hemorrhagic Clival Chordoma with a Long Progression-Free Survival
World Neurosurgery, 2017Chordomas and ecchordosis physaliphora may on rare occasions present with intracranial hemorrhage. Their distinction usually relies on the results of the Ki-67 proliferative index, with a result lower than 1% favoring ecchordosis physaliphora. Intracranial hemorrhagic chordomas have been linked to unfavorable prognosis, due to acute neurologic ...
Marcelo D. Vilela +3 more
openaire +2 more sources
Evaluating and Adjusting for Premature Censoring of Progression-Free Survival
Journal of Biopharmaceutical Statistics, 2013The intent-to-treat principle, grouping subjects as they were randomized and following all subjects to the endpoint or the end of study, allows valid statistical comparisons. Progression-free survival (PFS) has been used as a decision-making endpoint in oncology.
Hong Laura Lu +7 more
openaire +3 more sources
The Cancer Journal, 2009
In clinical trials of oncology drugs, overall survival (OS) is a direct measure of clinical efficacy and is considered the gold standard primary efficacy end point. The purpose of this study was to discuss the difficulties in using OS as a primary efficacy end point in the setting of evolving cancer therapies.
Andrea Kay +4 more
openaire +2 more sources
In clinical trials of oncology drugs, overall survival (OS) is a direct measure of clinical efficacy and is considered the gold standard primary efficacy end point. The purpose of this study was to discuss the difficulties in using OS as a primary efficacy end point in the setting of evolving cancer therapies.
Andrea Kay +4 more
openaire +2 more sources
Progression-free survival: it is time for a new name
The Lancet Oncology, 2022Bishal, Gyawali +3 more
openaire +2 more sources
VP87 Extrapolation From Progression Free Survival To Overall Survival In Oncology
International Journal of Technology Assessment in Health Care, 2017INTRODUCTION:The outcomes from clinical and other healthcare trials of most interest to patients and health systems are usually increases in the quality and length of life (overall survival (OS)). This poses a problem, because complete knowledge on the true increase in OS is not available until the last person in the trial dies.
Nicholas Latimer +3 more
openaire +2 more sources